Clinical efficacy of herbal fumigation on hand-foot syndrome after chemotherapy in colorectal cancer patients
-
摘要: 目的 观察中药熏洗治疗卡培他滨化疗后手足综合征的疗效。 方法 选取因口服卡培他滨出现Ⅱ级手足综合征的结直肠癌患者84例,随机分为治疗组和对照组,每组42例。对照组给予口服维生素B6及甲钴胺治疗; 治疗组在口服药物治疗的基础上加用中药熏洗治疗,比较2组治疗后疗效情况。 结果 对照组总有效率64.3%, 其中治愈率38.1%; 治疗组总有效率90.5%, 其中治愈率66.7%, 2组总有效率、治愈率差异具有统计学意义(P<0.05)。 结论 针对卡培他滨化疗后手足综合征患者在口服药物治疗基础上加用中药熏洗可提高治疗有效率和治愈率。Abstract: Objective To observe the effect of herbal fumigation on hand-foot syndrome after capecitabine chemotherapy. Methods Eighty-four colorectal cancer patients with Ⅱ degree of hand-foot syndrome induced by oral capecitabine for chemotherapy were randomly divided into control group and treatment group. Patients in the control group orally administrated vitamin B6 and mecobalamine, and those in the treatment group was additionally given herbal fumigation based on oral administration of drugs. The curative effects of the two groups were compared after treatment. Results The total effective rate was 64.3% in the control group, and 90.5% in the treatment group; the cure rate was 38.1% in the control group, and 66.7% in the treatment group, there were statistically significant differences in total effective rate and cure rate between the two groups(P<0.05). Conclusion Fumigation with traditional Chinese medicine based on oral administration of drugs can improve the effective rate and cure rate of hand-foot syndrome.
-
Keywords:
- capecitabine /
- hand-foot syndrome /
- herbal fumigation /
- vitamin B6 /
- mecobalamine /
- colorectal cancer
-
-
FREDDIE B, JACQUES F, ISABELLE S, et al. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. A Cancer Journal for Clinicians, 2018, 20(1): 1-20.
曹毛毛, 陈万青. 中国恶性肿瘤流行情况及防控现状[J]. 中国肿瘤临床, 2019, 46(3): 47-51. SIDDIQUI N S, GODARA A, BYRNE M M, et al. Capecitabine for the treatment of pancreatic cancer[J]. Expert Opinion on Pharmacotherapy, 2019: 1-11.
LAM S W, GUCHELAAR H J, BOVEN E. The role of pharmacogenetics in capecitabine efficacy and toxicity[J]. Cancer Treatment Reviews, 2016: 20-30.
SOO R A, SYN N, LEE S C, et al. Pharmacogenetics-Guided Phase Ⅰ Study of Capecitabine on an Intermittent Schedule in Patients with Advanced or Metastatic Solid Tumours[J]. Scientific Reports, 2016, 6(1): 27826.
SUTO T, ISHIGURO M, HAMADA C, et al. Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase Ⅲ study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage Ⅲ colon cancer[J]. International Journal of Clinical Oncology, 2017: 1-2.
ILYAS S, WASIF K, SAIF M W. Topical henna ameliorated capecitabine-induced hand-foot syndrome[J]. Cutaneous and Ocular Toxicology, 2014, 33(3): 253-255.
郭千弘, 马建瓴, 张炯, 等. 卡培他滨与5-氟尿嘧啶引起手足综合征的临床观察[J]. 中国医药指南, 2013, 15(31): 48-49 , 51.
GAOJ, HE Q, HUA D, et al. Polymorphism of TS 3'-UTR predicts survival of Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel[J]. clinical & translational oncology, 2013, 15(8): 619-625.
FABIAN C J, MOLINA R, SLAVIK M, et al. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion[J]. Investigational New Drugs, 1990, 8(1): 57-63.
LIN E, MORRIS J S, AYERS G D. Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity[J]. Oncology, 2002, 16(14): 31-37.
ZHANG X J, WU D S, WAN Z H, et al. Celecoxib can prevent capecitabine-related hand-foot syndrome in stage Ⅱ and Ⅲ colorectal cancer patients: result of a single-center, prospective randomized phase Ⅲ trial[J]. Annals of oncology: official journal of the European Society for Medical Oncology, 2012, 23(5): 1348-53.
李响, 刘铎, 吴东媛, 等. 卡培他滨相关基因多态性与手足综合征关系的研究进展[J]. 实用肿瘤学杂志, 2018, 32(2): 59-63. HAMZIC S, KUMMER D, MILESI S, et al. Novel genetic variants in carboxy lesterase 1 predict severe early-onset capecitabine-related toxicity[J]. Clinical Pharmacology & Therapeutics, 2017.
MARTIN M, MARTINEZ N, RAMOS M, et al. Standard Versus Continuous Administration of Capecitabine in Metastatic Breast Cancer(GEICAM/2009-05): A Randomized, Noninferiority Phase Ⅱ Trial With a Pharmacogenetic Analysis[J]. Oncologist, 2015, 20(2): 111-112.
PELLICER M, XANDRA. Identification of new SNPs associated with severe toxicity to capecitabine[J]. Pharmacological Research, 2017, 120: 133-137.
李荣振, 张思森, 杨铁健, 等. CDA基因变异对卡培他滨治疗结直肠癌患者出现手足综合征的影响[J]. 中国肿瘤临床, 2018, 45(9): 458-461. JO S J, SHIN H, JO S, et al. Prophylactic and therapeutic efficacy of pyridoxine supplements in the management of hand-foot syndrome during chemotherapy: a meta-analysis[J]. Clinical and Experimental Dermatology, 2015, 40(3): 260-270.
YAP Y S, KWOK L L, SYN N, et al. Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine–Induced Hand-Foot Syndrome[J]. JAMA Oncology, 2017, 29(6): 10-25.
MACEDO, LIMA J P N, SANTOS L V D, et al. Prevention strategies for chemotherapy-induced hand-foot syndrome: A systematic review and meta-analysis of prospective randomised trials[J]. Supportive Care in Cancer, 2014, 22(6): 15-25.
张晓迪, 陈嘉璐, 高静东. 温经化瘀方外治化疗相关性手足综合征的临床观察[J]. 浙江中医药大学学报, 2017, 41(2): 142-145. 马燕妮, 廖文静, 张军辉, 等. 为使用卡培他滨的恶性肿瘤患者进行中药熏洗治疗对其手足综合征发生率的影响[J]. 当代医药论丛, 2019, 17(13): 208-209. 董晶, 施航, 陆宁. 通阳活血方浸洗预防卡培他滨所致手足综合征临床观察[J]. 中国中医药科技, 2017, 24(6): 798-799.
计量
- 文章访问数: 343
- HTML全文浏览量: 124
- PDF下载量: 40
下载:
苏公网安备 32100302010246号
